CHF5993 pMDI (100) -152a clinical trials

A 52 week, randomized, double-blind, double dummy multinational, multicenter, active controlled, 2-arm parallel group trial comparing CHF 5993 100/6/12.5 µg pMDI (fixed combination of extrafine Beclomethasone Dipropionate plus Formoterol Fumarate plus Glycopyrronium Bromide) to Seretide® Evohaler® 125/25 µg pMDI (fixed combination of fluticasone propionate / salmeterol xinafoate) in adolescent subjects with asthma uncontrolled on medium doses of inhaled corticosteroids in combination with long acting ß2 agonists.

This study compares a new inhaler (CHF 5993) to a common asthma inhaler (Seretide Evohaler) in teenagers with asthma that isn't well controlled. It aims to see if the new inhaler helps breathing better and reduces asthma attacks.